Intangible Assets

TELA’s product set appears to rely on clinical utility rather than protected brand power, so peer pricing power is likely limited and not durable versus larger medtech competitors.

The provided TTM ROIC and ROCE are deeply negative, which indicates the company is not converting any perceived intangible advantage into economic returns better than peers.

No evidence in the supplied data suggests proprietary IP, regulatory exclusivity, or a differentiated clinical standard that would materially raise retention versus alternative wound-care or surgical peers.

In a market with established medtech incumbents, any brand or product recognition is more likely substitutable than structurally protected, which weakens long-term margin defense versus peers.

Switching Costs

The business does not appear to embed high workflow lock-in, so customers can likely switch to alternative products without major system-wide disruption compared with software-like peers.

Negative ROIC and ROCE suggest the company is not monetizing customer retention through durable repeat purchasing power better than peers.

The supplied metrics do not show evidence of contractual lock-in, installed-base dependence, or integration depth that would materially raise switching costs over a 5–10 year horizon.

Compared with stronger medtech peers that benefit from procedure standardization or capital equipment ecosystems, TELA’s switching costs appear limited and easier to replicate.

Network Effects

TELA does not appear to operate a platform where more users, providers, or data materially improve the product for other users, so network effects are likely absent.

The available metrics provide no sign of ecosystem compounding, referral loops, or data advantages that would strengthen retention versus peers.

Unlike peer businesses with physician networks, payer networks, or digital usage flywheels, TELA’s value proposition appears product-based rather than network-based.

Without a self-reinforcing user or data loop, any competitive advantage is unlikely to widen over time relative to peers.

Cost Advantage

The negative ROIC and ROCE indicate TELA is not demonstrating a cost position that converts into superior returns versus peers.

A cash conversion cycle of about 160 days suggests working-capital intensity rather than a structurally lean cost base, which weakens pricing resilience.

No supplied evidence points to scale purchasing, manufacturing efficiency, or logistics advantages that would lower unit costs versus larger competitors.

Compared with larger medtech peers that can spread fixed R&D, regulatory, and commercial costs over broader revenue bases, TELA appears disadvantaged on cost leverage.

Efficient Scale

TELA does not appear to operate in a clearly natural-monopoly niche where one or two firms can serve the market more efficiently than many rivals.

The company’s negative returns suggest it has not yet reached a scale position that protects margins or deters entry better than peers.

No evidence in the provided data indicates that market size is so limited that incumbent scale creates durable pricing power or industry stability.

Compared with peers that benefit from concentrated hospital relationships or high fixed-cost manufacturing scale, TELA’s scale position appears insufficient to create a durable moat.

Overall Score

TELA’s moat appears weak versus peers because the supplied metrics show deeply negative capital returns, no visible switching-cost or network-effect engine, and no evidence of a durable cost or scale advantage; any competitive differentiation looks more replicable than structurally protected.